Literature DB >> 26551850

[Validation of SHI Claims Data Exemplified by Gender-specific Diagnoses].

J Hartmann1, C Weidmann1, R Biehle1.   

Abstract

Aim: Use of statutory health insurance (SHI) data in health services research is increasing steadily and questions of validity are gaining importance. Using gender-specific diagnosis as an example, the aim of this study was to estimate the prevalence of implausible diagnosis and demonstrate an internal validation strategy. Method: The analysis is based on the SHI data from Baden-Württemberg for 2012. Subject of validation are gender-specific outpatient diagnoses that mismatch with the gender of the insured. To uncover this implausibility, it is necessary to clarify whether the diagnosis or the gender is wrong. The validation criteria used were the presence of further gender-specific diagnoses, the presence of gender-specific settlement items, the specialization of the physician in charge and the gender assignment of the first name of the insured. To review the quality of the validation, it was verified if the gender was changed during the following year.
Results: Around 5.1% of all diagnoses were gender-specific and there was a mismatch between diagnosis and gender in 0.04% of these cases. All validation criteria were useful to sort out implausibility, whereas the last one was the most effective. Only 14% remained unsolved. From the total of 1 145 insured with implausible gender-specific diagnoses, one year later 128 had a new gender (in the data). 119 of these cases were rightly classified as insured with wrong gender and 9 cases were in the unsolved group. This confirms that the validation works well.
Conclusion: Implausibility in SHI data is relatively small and can be solved with appropriate validation criteria. When validating SHI data, it is advisable to question all data used critically, to use multiple validation criteria instead of just one and to abandon the idea that reality and the associated data conform to standardized norms. Keeping these aspects in mind, analysis of SHI data is a good starting point for research in health services. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26551850     DOI: 10.1055/s-0035-1565072

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  5 in total

Review 1.  Individual Data Linkage of Survey Data with Claims Data in Germany-An Overview Based on a Cohort Study.

Authors:  Stefanie March
Journal:  Int J Environ Res Public Health       Date:  2017-12-09       Impact factor: 3.390

2.  Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study.

Authors:  Luisa Ibáñez; Mònica Sabaté; Xavier Vidal; Elena Ballarin; Marietta Rottenkolber; Sven Schmiedl; Andreas Heeke; Consuelo Huerta; Elisa Martin Merino; Dolores Montero; Luz María Leon-Muñoz; Christiane Gasse; Nicholas Moore; Cécile Droz; Régis Lassalle; Mia Aakjaer; Morten Andersen; Marie Louise De Bruin; Rolf Groenwold; Hendrika A van den Ham; Patrick Souverein; Olaf Klungel; Helga Gardarsdottir
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

3.  Healing, surviving, or dying? - projecting the German future disease burden using a Markov illness-death model.

Authors:  Valeska Milan; Stefan Fetzer; Christian Hagist
Journal:  BMC Public Health       Date:  2021-01-11       Impact factor: 3.295

4.  Use of Biologic Therapies in the Treatment of Asthma - A Comparative Real World Data Analysis on Healthcare Resource Utilization and Costs Before and After Therapy Initiation.

Authors:  Fraence Hardtstock; Julia Krieger; Thomas Wilke; Marco Lukas; Bernhard Ultsch; Robert Welte; Renate Quinzler; Ulf Maywald; Hartmut Timmermann
Journal:  J Asthma Allergy       Date:  2022-04-05

5.  Epidemiology and treatment of patients with Chronic rhinosinusitis with nasal polyps in Germany-A claims data study.

Authors:  Alexandra Starry; Fraence Hardtstock; Thomas Wilke; Julia Weihing; Bernhard Ultsch; Martin Wernitz; Marius Renninger; Ulf Maywald; Oliver Pfaar
Journal:  Allergy       Date:  2022-04-08       Impact factor: 14.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.